UC, UC Health to launch Phase 3 clinical trial for COVID-19 vaccine

Researchers at the University of Cincinnati and UC Health will host a Phase 3 clinical trial to evaluate the effectiveness of a vaccine for COVID-19, the respiratory illness caused by the novel coronavirus SARS-CoV-2.

UC is one of approximately 90 sites across the United States selected for the study, which will administer the vaccine candidate mRNA-1273 to volunteer participants and monitor its efficacy in eliciting an immune response that provides protection from COVID-19. The National Institute of Allergy and Infectious Diseases, (NIAID), part of the National Institutes of Health, is funding the study.

/University Release. The material in this public release comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.